Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.
Biotech funding optimism rises as 44% predict recovery in 2024 – Pharmaceutical Technology
Share this article Figure 1: Percentage growth of total private biotech venture financing deal volume/value for innovator drugs in the US from 2013–2023. Source: GlobalData
March 1, 2024